Ernexa Therapeutics Inc.: Form 10-Q for the period ended Sep 30, 2011
Filed with the SEC on Nov 14, 2011 and accepted by EDGAR at Nov 14, 2011, 12:57 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2011-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2011-07-01 to 2011-09-30 | $5.9m | us-gaap:SalesRevenueNet |
| Revenue | 9 months2011-01-01 to 2011-09-30 | $17.8m | us-gaap:SalesRevenueNet |
| Selling, general and administrative | 3 months2011-07-01 to 2011-09-30 | $5.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2011-01-01 to 2011-09-30 | $15.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2011-07-01 to 2011-09-30 | −$795.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2011-01-01 to 2011-09-30 | −$2.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2011-07-01 to 2011-09-30 | $37.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2011-01-01 to 2011-09-30 | $48.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2011-07-01 to 2011-09-30 | −$837.0k | us-gaap:NetIncomeLoss |
| Net income | 9 months2011-01-01 to 2011-09-30 | −$2.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2011-07-01 to 2011-09-30 | −$0.01 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2011-01-01 to 2011-09-30 | −$0.04 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2011-07-01 to 2011-09-30 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2011-01-01 to 2011-09-30 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2011-07-01 to 2011-09-30 | 60,404,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2011-01-01 to 2011-09-30 | 60,394,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2011-01-01 to 2011-09-30 | $701.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2011-01-01 to 2011-09-30 | $1.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2011-09-30 | $2.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2011-09-30 | $3.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2011-09-30 | $12.2m | us-gaap:Assets |
| Current liabilities | At period end2011-09-30 | $3.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2011-09-30 | $4.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2011-09-30 | $7.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001019687-11-003500. Last ingested by Listed: Nov 6, 2026, 17:52 ET. Listed shows no prices and gives no investment advice.